Completed PHASE3 INTERVENTIONAL 2-arm NCT00255190

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

A Phase 3, Open-Label Study to Assess the Long-Term Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD)

Sponsor: Takeda

Conditions Gastroesophageal Reflux Disease

Updated 8 times since 2017 Last updated: Jun 27, 2016 Started: Jan 31, 2006 Primary completion: Jun 30, 2008 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Gastroesophageal Reflux Disease, this trial is completed. The trial is conducted by Takeda and has accumulated 8 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Alabaster, United States , Albuquerque, United States , Amarillo, United States , Anaheim, United States , Anderson, United States , Anniston, United States , Arlington Heights, United States , Atlanta, United States , Austin, United States and 168 more locations